Liminatus Pharma Reduces Stockholder Meeting Quorum to One-Third
LIMN is trading near its 52-week low of $0.21 (14% above the low) on light trading volume (0.1× avg).
Summary
Liminatus Pharma's Board reduced the quorum for stockholder meetings from a majority to one-third, potentially streamlining future corporate actions and altering shareholder influence.
Key Events · Corporate Governance and Compliance · LIMN
-
Bylaw Amendment Approved
The Board of Directors approved an amendment to the company's bylaws on February 27, 2026.
-
Quorum Requirement Reduced
The amendment reduces the quorum for stockholder meetings from a majority to one-third (1/3) of the voting power of outstanding capital stock.
-
Board Retains Authority
The Board will seek stockholder ratification but has the authority to maintain the amendment even if not approved by stockholders.
Analysis · LIMN · Life Sciences
The Board of Directors of Liminatus Pharma, Inc. approved an amendment to its bylaws, significantly reducing the quorum requirement for stockholder meetings from a majority to one-third of the voting power. This change, effective immediately, could streamline future corporate actions by making it easier to achieve a quorum and pass resolutions. While the amendment will be submitted for stockholder ratification, the Board retains the authority to maintain it under Delaware law even if not ratified. This governance change may be viewed as reducing the influence of a dispersed shareholder base.
At the time of this filing, LIMN was trading at $0.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.7M. The 52-week trading range was $0.21 to $33.66. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.